Summary
Several studies indicate that the short arm of chromosome 17 is one of the most frequently altered regions in sporadic breast carcinomas (45–60%). In the present report the 17p13.3-ter locus in tumour DNA of breast cancer patients, along with their matching normal lymphocyte DNA, have been mapped with four markers (D17S5, D17S379, ABR and D17S34), spanning nearly 3 cM of the telomer. Sixty-five of 143 heterozygous tumours had lost at least one of the markers at the minimum region of loss (45%). High levels of loss of these distal markers on 17p13.3 are independent of TP53 mutations and are associated with tumour cell proliferation. A follow-up period of over 7 years demonstrates that loss of these markers correlates both with disease-free (P = 0.004) and overall survival (P = 0.007). In addition we show that for disease-free survival the prognostic power of this genetic alteration is second only to axillary lymph node involvement (3.1 vs 6.3 relative risk), and is a better predictor than the mutational status of TP53 (1.6 relative risk). Our results are further evidence of the presence, within the region, of at least a second tumour suppressor gene distal to TP53, that might be targeted by deletions.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Bonadonna, G., Valagussa, P., Tancini, G., Rossi, A., Brambilla, C., Zambetti, M., Bignami, P., Di Fronzo, G. & Silvestrini, R. (1986). Current status of Milan adjuvant chemotherapy trials for node-positive and node-negative breast cancer. Natl Cancer Inst Monogr 1: 45–49.
Carrozzo, R. & Ledbetter, D. H. (1993). Dinucleotide repeat polymorphism mapping to the critical region for lissencephaly (17p 13.3). Hum Mol Genet 2: 615
Coles, C., Thompson, A. M., Elder, P. A., Cohen, B. B., Mackenzie, I. M., Cranston, G., Chetty, U., Mackay, J., Macdonald, M., Nakamura, Y., Hoyheim, B. & Steel, C. M. (1990). Evidence implicating at least two genes on chromosome 17p in breast carcinogenesis. Lancet 336: 761–763.
Cox, D. R. (1972). Regression models and life tables. J R Stat Soc 34: 187–220.
Gudmundsson, J., Johannesdottir, G., Bergthorsson, J. T., Arason, A., Ingvarsson, S., Egilsson, V. & Barkardottir, R. B. (1995). Different tumor types from BRCA2 carriers show wild-type chromosome deletions on 13q12–q13. Cancer Res 55: 4830–4832.
Heisterkamp, N., Kaartinen, V., van Soest, S., Bokoch, G. M. & Groffen, J. (1993). Human ABR encodes a protein with GAP-rac activity and homology to the DBL nucleotide exchange factor domain. J Biol Chem 268: 16903–16906.
Isomura, M., Tanigami, A., Saito, H., Harada, Y., Katagiri, T., Inazawa, J., Ledbetter, D. H. & Nakamura, Y. (1994). Detailed analysis of LOH on chromosome band 17p13 in breast carcinoma on the basis of a high-resolution physical map with 29 markers. Genes Chromosomes Cancer 9: 173–179.
Knudson, A. G. (1985). Hereditary cancer, oncogenes and antioncogenes. Cancer Res 45: 1437–1443.
Lancaster, J. M., Wooster, R., Mangion, J., Phelan, C. M., Cochran, C., Gumbs, C., Seal, S., Barfoot, R., Collins, N., Bignell, G., Patel, S., Hamoudi, R., Larsson, C., Wiseman, R. W., Berchuck, A., lglehart, J. D., Marks, J. R., Ashworth, A., Stratton, M. R. & Futreal, P. A. (1996). BRCA2 mutations in primary breast and ovarian cancers. Nat Genet 13: 238–240.
Lindblom, A., Skoog, L., Andersen, T. I., Rotstein, S., Nordenskjold, M. & Larsson, C. (1993). Four separate regions on chromosome 17 show loss of heterozygosity in familial breast carcinomas. Hum Genet 91: 6–12.
Mackay, J., Steel, C. M., Elder, P. A., Forrest, A. P. & Evans, H. J. (1988). Allele loss on short arm of chromosome 17 in breast cancers. Lancet ii: 1384–1385.
Makos, M., Biel, M. A., Deiry, W. E., Nelkin, B. D., Issa, J. P., Cavenee, W. K., Kuerbitz, S. J. & Baylin, S. B. (1995). p53 activates expression of HIC-1, a new candidate tumour suppressor gene on 17p13.3. Nature Med 1: 570–577.
Merlo, G. R., Venesio, T., Bernardi, A., Cropp, C. S., Diella, F., Cappa, A. P. M., Callahan, R. & Liscia, D. S. (1994). Evidence for a second tumour suppressor gene on chromosome 17p linked to high S-phase index in primary human breast carcinomas. Cancer Genet Cytogenet 76: 106–111.
Meroni, G., Reymond, A., Alcalay, M., Borsani, G., Tanigami, A., Tonlorenzi, R., Lo Nigro, C., Messali, S., Zollo, M., Ledbetter, D. H., Brent, R., Ballabio, A. & Carrozzo, R. (1997). Rox, a novel bHLHZip protein expressed in quiescent cells that heterodimerizes with Max, binds a non-canonical E Box and acts as a transcriptional repressor. EMBO J 16: 2892–2906.
Milner, J. & Medcalf, E. A. (1991). Cotranslation of activated mutant p53 with wild type drives the wild type p53 protein into the mutant conformation. Cell 65: 765–774.
Mittra, I. & MacRae, K. D. (1991). A meta-analysis of reported correlations between prognostic factors in breast cancer: does axillary lymph node metastasis represent biology or chronology?. Eur J Cancer 27: 1574–1583.
Morris, C., Benjes, S., Haataja, L., Ledbetter, D. H., Heisterkamp, N. & Groffen, J. (1995). Spatial organization of ABR and CRK genes on human chromosome band 17p13.3. Oncogene 10: 1009–1011.
Nagai, M. A., Pacheco, M. M., Brentani, M. M., Marques, L. A., Brentani, R. R., Ponder, B. A. & Mulligan, L. M. (1994). Allelic loss on distal chromosomes 17p is associated with poor prognosis in a group of Brazilian breast-cancer patients. Br J Cancer 69: 754–758.
Nakamura, Y., Ballard, L., Leppert, M., O’Connel, P., Lathrop, G. M., Lalouel, J. M. & White, R. (1988). Isolation and mapping of a polymorphic DNA sequence (pYNZ22) on chromosome 17p [D17S30]. Nucleic Acids Res 16: 570–.
Neuhausen, S. L. & Marshall, C. J. (1994). Loss of heterozygosity in familial tumors from three BRCA1-linked kindreds. Cancer Res 54: 6069–6072.
Radford, D. M., Fair, K. L., Phillips, N. J., Ritter, J. H., Steinbrueck, T., Holt, M. S. & Donis-Keller, H. (1995). Allelotyping of ductal carcinoma in situ of the breast: deletion of loci on 8p, 13q, 16q, 17p and 17q. Cancer Res 55: 3399–3405.
Sato, T., Tanigami, A., Yamakawa, K., Akiyama, F., Kasumi, F., Sakamoto, G. & Nakamura, Y. (1990). Allelotype of breast cancer: cumulative allele losses promote tumour progression in primary breast cancer. Cancer Res 50: 7184–7189.
Schultz, D. C., Vanderveer, L., Berman, D. B., Hamilton, T. C., Wong, A. J. & Godwin, A. K. (1996). Identification of two candidate tumor suppressor genes on chromosome 17p13.3. Cancer Res 56: 1997–2002.
Sidransky, D., Takashi, T., Helzlsouer, K., Zehnbauer, B., Rausch, G., Shelton, B., Prestigiacomo, L., Vogelstein, B. & Davidson, N. (1992). Inherited p53 gene mutations in breast cancer. Cancer Res 52: 2984–2986.
Sjögren, S., Inganas, M., Norberg, T., Lindgren, A., Nordgren, H., Holmberg, L. & Bergh, J. (1996). The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J Natl Cancer Inst 88: 173–182.
Stack, M., Jones, D., White, G., Liscia, D. S., Venesio, T., Casey, G., Crichton, D., Varley, J., Mitchell, E., Heighway, J. & Santibanez-Koref, M. (1995). Detailed mapping and loss of heterozygosity analysis suggests a suppressor locus involved in sporadic breast cancer within a distal region of chromosome band 17. Hum Mol Genet 4: 2047–2055.
Theile, M., Hartmann, S., Scherthan, H., Arnold, W., Deppert, W., Frege, R., Glaab, F., Haensch, W. & Scherneck, S. (1995). Suppression of tumorigenicity of breast cancer cells by transfer of human chromosome 17 does not require transferred BRCA1 and p53 genes. Oncogene 10: 439–447.
White, G. R. M., Stack, M., Santibanez-Koref, M., Liscia, D. S., Venesio, T., Wang, J. C., Helms, C., Donis-Keller, H., Betticher, D. C., Altermatt, H. J., Hoban, P. R. & Heighway, J. (1996). High levels of loss at the 17p telomere suggest the close proximity of a tumour suppressor. J Cancer 74: 863–870.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Liscia, D., Morizio, R., Venesio, T. et al. Prognostic significance of loss of heterozygosity at loci on chromosome 17p13.3-ter in sporadic breast cancer is evidence for a putative tumour suppressor gene. Br J Cancer 80, 821–826 (1999). https://doi.org/10.1038/sj.bjc.6690427
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.bjc.6690427
Keywords
This article is cited by
-
miR-762 activation confers acquired resistance to gefitinib in non-small cell lung cancer
BMC Cancer (2019)
-
Papillary lesions of the breast: a molecular progression?
Breast Cancer Research and Treatment (2005)
-
Identification of a second G–C-rich promoter conserved in the human, murine and rat tumor suppressor genes HIC1
Oncogene (2004)
